- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Predictive Value of Diagnostic Testing
Peter Salgo, MD, and John L. Fox, MD, MHA, discuss the definition of predictive value of diagnostic testing in cancer and describe the value of the genomic assays that are currently available in breast cancer.
Dr Fox defines predictive value as “something that helps define optimal therapy for a patient.” As an example, he describes how the detection of certain mutations in colorectal cancer can suggest that a patient will respond to a specific drug. In contrast, the genomic assays in breast cancer predict a general response to chemotherapy but they do not provide information on what specific drug or drug combination the patient would respond to. A test with strong predictive value can help provide more clarity about which treatment is most appropriate for the patient, comments Dr Fox.
Currently, the diagnostic tests in breast cancer only indicate the likelihood that a patient may respond to chemotherapy. Dr Fox is hopeful that in the future, predictive testing will help determine whether or not patients are responding to treatment.
Watch our related Peer Exchange, Oncology Stakeholder Summit 2014: Evidence-Based Decisions to Improve Quality and Regulate Costs
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
